Table 2 Summary of patient characteristics at baseline

Patients, n

333

333

Sex, n (%)

Male

160

(48.0)

218

(65.5)

p < 0.0001

Female

173

(52.0)

115

(34.5)

Age, mean (SD)

Male

75.7

(9.2)

69.5

(11.9)

p < 0.0001

Female

77.7

(8.5)

73.5

(13.8)

Reason for OAT, n (%)

Heart arrhythmia due to atrial fibrillation

242

(72.7)

221

(66.4)

0.051

Aortic prosthesis

24

(7.2)

43

(12.9)

Deep vein thrombosis

15

(4.5)

23

(6.9)

Mitral valve prosthesis

17

(5.1)

17

(5.1)

Pulmonary thromboembolism

21

(6.3)

10

(3.0)

Cerebrovascular accident

7

(2.1)

5

(1.5)

Deficit proteins

0

(0.0)

4

(1.2)

Others

3

(0.9)

4

(1.2)

Valvular heart disease

3

(0.9)

4

(1.2)

Ischemic heart disease

1

(0.3)

2

(0.6)

INR ranges n (%)

1.5–2.5

0

(0.0)

1

(0.3)

0.029

2.0–3.0

287

(86.2)

264

(79.3)

2.5–3.5

46

(13.8)

68

(20.4)

Length of treatment,

1–3

96

(29.0)

85

(25.7)

0.77

years (%)

4–7

105

(31.7)

106

(32.0)

8–10

52

(15.7)

54

(16.3)

>10

78

(23.6)

86

(26.0)

Risk factors,

Arterial hypertension

217

(37.8)

196

(37.9)

0.132

n (%)

Diabetes mellitus

85

(14.8)

69

(14.4)

Hyperlipaemia

169

(29.5)

180

(34.1)

Cancer

50

(9.2)

35

(6.8)

Liver disease

6

(1.3)

14

(1.5)

Kidney disease

40

(7.4)

32

(5.3)

Polypharmacy, n (%)

1–3 drugs

70

(21.3)

102

(39.5)

p < 0.0001

4–7 drugs

139

(42.6)

156

(37.2)

8–12 drugs

108

(30.9)

59

(19.8)

13 or more drugs

16

(5.1)

16

(3.5)

Other,

Independent

226

(67.9)

219

(65.8)

0.621

n (%)

Caregiver

107

(32.1)

114

(34.2)